EUVIMEDEUVIMED entdecken
Open Access

Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report

Rupak Datta, Sonali Advani, Andrea Rink, Luann Bianco, Peter H Van Ness, Vincent Quagliarello, Manisha Juthani-Mehta

Open Access Journal of Gerontology & Geriatric Medicine · 22.05.2018 · 4 (3)

DOI: 10.19080/oajggm.2018.04.555636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Access Journal of Gerontology & Geriatric Medicine, online erschienen am 22.05.2018. Verfasst von Rupak Datta und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Suspected urinary tract infection is a common indication for antimicrobial therapy in long-term care residents. We sought to characterize antimicrobial susceptibilities among urine isolates collected from women long-term care residents enrolled in a clinical trial across 21 long-term care facilities in Connecticut, United States of America between August 2012 and October 2015. Among 967 urine cultures collected from 175 women long-term care residents with and without suspected urinary tract infection, we identified 456 bacterial isolates. Escherichia coli (55.3%), Klebsiella (13.8%) and Enterococcus (8.3%) species were the predominant organisms identified. Among all 456 urine isolates, 68.1% were ciprofloxacin-susceptible, 77.2% were trimethoprim/sulfamethoxazole-susceptible, 86.3% were cefazolin-susceptible, and 72.6% were nitrofurantoin-susceptible. Among 252 Escherichia coli urine isolates, 60.2% were ciprofloxacin-susceptible, 73.7% were trimethoprim/ sulfamethoxazole-susceptible, 84.5% were cefazolin-susceptible, and 86.5% were nitrofurantoin-susceptible. These findings suggest that trimethoprim/sulfamethoxazole may be favorable empiric therapy while the urinary isolate is unknown, and nitrofurantoin may be optimal therapy for uncomplicated urinary tract infection due to Escherichia coli in women long-term care residents.

Schlagwörter

Stichwörter der Autor:innen

Antibiotic SusceptibilityEscherichia coliLong-Term Care ResidentsNitrofurantoinUrinary Tract Infection

Autor:innen und Institutionen

  • Department of Internal Medicine, Section of Infectious Diseases, Yale School of Medicine, New Haven, CT USA.
  • Department of Internal Medicine, Section of Geriatrics, Yale School of Medicine, New Haven, CT USA.

Förderung

  • NIA NIH HHS
  • NIAID NIH HHS

Zitieren

APA

Datta, R., Advani, S., Rink, A., Bianco, L., Van Ness, P. H., Quagliarello, V., & Juthani-Mehta, M. (2018). Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report. Open Access Journal of Gerontology & Geriatric Medicine, 4(3). https://doi.org/10.19080/oajggm.2018.04.555636

Vancouver

Datta R, Advani S, Rink A, Bianco L, Van Ness PH, Quagliarello V, et al. Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report. Open Access Journal of Gerontology & Geriatric Medicine. 2018;4(3). doi:10.19080/oajggm.2018.04.555636

BibTeX
@article{Datta2018,
  author = {Datta, Rupak and Advani, Sonali and Rink, Andrea and Bianco, Luann and Van Ness, Peter H and Quagliarello, Vincent and Juthani-Mehta, Manisha},
  title = {Increased Fluoroquinolone-Susceptibility and Preserved Nitrofurantoin-Susceptibility among Escherichia coli Urine Isolates from Women Long-Term Care Residents: A Brief Report},
  journal = {Open Access Journal of Gerontology & Geriatric Medicine},
  year = {2018},
  volume = {4},
  number = {3},
  doi = {10.19080/oajggm.2018.04.555636}
}
Kostenlos starten →